Retrospective comparison of ultrasound facilitated catheter-directed thrombolysis and systemically administered half-dose thrombolysis in treatment of pulmonary embolism.


Journal

Vascular medicine (London, England)
ISSN: 1477-0377
Titre abrégé: Vasc Med
Pays: England
ID NLM: 9610930

Informations de publication

Date de publication:
Apr 2019
Historique:
pubmed: 6 3 2019
medline: 29 5 2019
entrez: 6 3 2019
Statut: ppublish

Résumé

This study retrospectively compared the outcomes of patients who received ultrasound facilitated catheter-directed thrombolysis (UFCDT) versus systemically administered 'half-dose' thrombolysis (HDT) in 97 patients with PE. The outcomes assessed included changes in baseline pulmonary artery systolic pressure (PASP), right ventricle/left ventricle ratio (RV/LV), cost and duration of hospitalization, death, bleeding, and recurrent venous thromboembolism in the short and intermediate term follow-up. Analyses were performed using a covariance adjustment propensity score approach to address baseline differences between groups in variables associated with PASP and RV/LV, covarying baseline scores. The baseline mean ± SE PASP dropped from 49.3 ± 1.1 to 32.5 ± 0.3 mmHg at 36 hours in the HDT group, and from 50.6 ± 1.2 to 35.1 ± 0.4 mmHg in the UFCDT group; group × time interaction p-value = 0.007. Corresponding drops in the RV/LV were from a baseline of 1.26 ± 0.05 to 1.07 ± 0.01 in the HDT group and from 1.30 ± 0.05 to 1.14 ± 0.01 in the UFCDT group at 36 hours; group × time interaction p-value = 0.269. Statistically significant decreases were noted in PASP and RV/LV for both the HDT and UFCDT at 36 hours and follow-up. PASP through follow-up was significantly lower in the HDT than the UFCDT group. Likewise, RV/LV was lower in the HDT group. The duration and cost of hospitalization were lower in the HDT group (6.2 ± 1.4 days vs 1.9 ± 0.3 days, p < 0.001; US$12,000 ± $3000 vs $74,000 ± $6000, p < 0.001). We conclude that both UFCDT and HDT lead to rapid reduction of PASP and RV/LV, whereas HDT leads to a lower duration and cost of hospitalization.

Identifiants

pubmed: 30834822
doi: 10.1177/1358863X18824159
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-109

Auteurs

Mohsen Sharifi (M)

1 Arizona Cardiovascular Consultants & Vein Clinic, Mesa, AZ, USA.
2 A.T. Still University, Mesa, AZ, USA.
3 Banner Health System, Mesa, AZ, USA.

Alan Awdisho (A)

1 Arizona Cardiovascular Consultants & Vein Clinic, Mesa, AZ, USA.

Bethany Schroeder (B)

1 Arizona Cardiovascular Consultants & Vein Clinic, Mesa, AZ, USA.

José Jiménez (J)

1 Arizona Cardiovascular Consultants & Vein Clinic, Mesa, AZ, USA.
3 Banner Health System, Mesa, AZ, USA.

Priya Iyer (P)

2 A.T. Still University, Mesa, AZ, USA.

Curt Bay (C)

2 A.T. Still University, Mesa, AZ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH